PeptiDream
Logotype for PeptiDream Inc

PeptiDream (4587) investor relations material

PeptiDream Q3 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for PeptiDream Inc
Q3 2026 earnings summary11 Nov, 2026

Executive summary

  • Nine-month revenue rose 15.3% YoY to ¥14,820 million; operating loss narrowed to ¥2,867 million and net loss attributable to owners narrowed to ¥2,363 million.

  • Full-year 2026 guidance remains unchanged, with revenue of ¥32,000 million and operating profit of ¥4,600 million; second-half upfront and R&D milestone revenue is expected to support full-year operating profit.

Financial highlights

  • Revenue increased by ¥1,963 million YoY to ¥14,820 million; gross profit rose to ¥6,960 million from ¥4,835 million.

  • Operating loss narrowed by ¥1,191 million YoY to ¥2,867 million; core operating loss narrowed by ¥1,175 million to ¥2,804 million.

  • Loss before tax was ¥3,154 million versus ¥4,340 million YoY; net loss was ¥2,363 million versus ¥3,217 million, and basic EPS was -¥18.35 versus -¥24.88.

  • Finance costs were ¥429 million, versus finance income of ¥146 million; income tax benefit was ¥791 million.

Outlook and guidance

  • FY2026 forecast: revenue ¥32,000 million, core operating profit ¥4,600 million, operating profit ¥4,600 million, profit before tax ¥4,300 million and net profit ¥3,000 million; guidance unchanged.

  • Full-year operating profit is expected to be supported by upfront payments under drug discovery and development agreements and R&D milestone revenue in H2.

  • FY2026 forecasts include capital expenditures of ¥5,449 million, depreciation of ¥1,922 million, R&D expenses of ¥6,445 million and period-end headcount of 810.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next PeptiDream earnings date

Logotype for PeptiDream Inc
Investor update8 Dec, 2026
PeptiDream
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next PeptiDream earnings date

Logotype for PeptiDream Inc
Investor update8 Dec, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

PeptiDream Inc. is a Japan-based biotechnology company specializing in peptide-based drug discovery and development. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to identify and optimize peptide therapeutics for various medical applications. PeptiDream collaborates with global pharmaceutical companies to develop novel therapeutics across multiple disease areas. Its research and development efforts focus on peptide-drug conjugates, small-molecule drugs, and peptide-based imaging agents. The company is headquartered in Kawasaki, Japan, and its shares are listed on the TSE.